M2Bio Sciences develops innovative healthcare solutions through cannabis and mushroom-based sciences. They focus on the active compounds found in mushrooms (psilocybin) and cannabis (cannabinoids). M2Bio Sciences conducts drug target discovery, pre-clinical trials, clinical trials, and aims for FDA approval. With an estimated $100 billion global total addressable market for psychedelics and a projected $97.35 billion medical cannabis market by 2026, M2Bio Sciences aims to provide substantial clinical improvement over existing therapies and improve the lives of consumers through scientific research.
Acquisition | Date | Source | Price | Acquired Company Sub-Sectors | Acquired Company Sectors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
